. 2018 Oct 16;11:89. doi: 10.1186/s13048-018-0463-3

Table 3.

FCCP pretreatment sensitize Kuramochi cultures to TRAIL and oligomycin A increases baseline Kuramochi culture viability

A		TRAIL
A		Untreated	50 ng/mL	100 ng/mL	ANOVA
FCCP (μM)	Vehicle	1.00 ± 0.08^a	1.00 ± 0.06^a	0.94 ± 0.07^a	0.7702
	1.0	0.89 ± 0.03^a,b	0.72 ± 0.03^b*	0.74 ± 0.03^a*	0.009
	2.5	0.74 ± 0.03^b,c	0.67 ± 0.02^b	0.60 ± 0.02^b*	0.0233
	5.0	0.66 ± 0.02^c	0.58 ± 0.06^b	0.57 ± 0.05^b	0.3392
ANOVA		0.0035	0.0009	0.002
B		Cisplatin
B		Untreated	1 μM	10 μM	ANOVA
FCCP (μM)	Vehicle	1.00 ± 0.06^a	0.97 ± 0.13^a	1.11 ± 0.02^a	0.5124
	1.0	0.89 ± 0.01^a	0.82 ± 0.10^a	0.85 ± 0.01^b	0.6946
	2.5	0.99 ± 0.09^a	0.78 ± 0.08^a	0.75 ± 0.01^c	0.0941
	5.0	0.90 ± 0.01^a	0.74 ± 0.10^a	0.78 ± 0.04^b,c	0.23
ANOVA		0.3707	0.4635	7.78E-06
C		TRAIL
C		Untreated	50 ng/mL	100 ng/mL	ANOVA
Oligomycin (μM)	Vehicle	1.00 ± 0.02^a	0.96 ± 0.14^a	1.08 ± 0.03^a	0.5539
	1.0	1.37 ± 0.00^b	1.15 ± 0.07^a	1.26 ± 0.07^a	0.093
	2.5	1.38 ± 0.12^b	1.14 ± 0.15^a	1.31 ± 0.04^a	0.353
	5.0	1.36 ± 0.05^b	1.19 ± 0.16^a	1.25 ± 0.05^a	0.535
ANOVA		0.0082	0.6272	0.0503
D		Cisplatin
D		Untreated	1 μM	10 μM	ANOVA
Oligomycin (μM)	Vehicle	1.00 ± 0.01^a	0.99 ± 0.01^a	1.01 ± 0.02^a	0.6714
	1.0	1.46 ± 0.18^a,b	1.29 ± 0.16^a	1.62 ± 0.03^b	0.3404
	2.5	1.83 ± 0.06^b	1.21 ± 0.04^a**	1.55 ± 0.09^b,c*	0.0014
	5.0	1.23 ± 0.08^a	1.10 ± 0.04^a	1.13 ± 0.02^a	0.2911
ANOVA		0.003	0.1401	4.23E-05

Resistance of Kuramochi cultures to cell death inducing agents TRAIL or cisplatin was analyzed through inhibition of OXPHOS using oligomycin A and a mitochondrial membrane potential uncoupler, FCCP, using MTS viability assays. Results are presented as fold change to vehicle treated control cultures with differing letters indicating significant (p < 0.05) changes in viability with treatment of inhibitor, and asterisks indicating significant (* p < 0.05; ** p < 0.01) changes in viability with treatment of cytotoxic agent. (A) Pretreatment with FCCP resulted in reduced culture viability following treatment with TRAIL, (B) but not cisplatin. (C) Oligomycin treatment increased culture viability, when compared to vehicle, but did not sensitize Kuramochi cultures to TRAIL. (D) Pretreatment with 2.5 μM oligomycin A sensitized Kuramochi cultures to decrease viability following cisplatin treatment